Immunomedics (IMMU) - moderated Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Fitzhughlaw who wrote (43265)	6/14/2017 5:15:28 PM
From: GCowan	Read Replies (2) of 63324

Hallo - you seem like an angry little man, but seem to be knowledgeable of the company. I found this abstract from ASCO abstracts.asco.org It essentially implies that they have made significant progress in categorizing TNBC into subsegments. This is of great important to what my colleagues and I consider to be relevant in the field, and furthermore has excellent implications for IMMU-132 P3 trials, as they will be able to tailor their treatment to a more specific patient which should yield wonder for the ORR. There was a write up on this in a cancer journal which coincided with an uptick in the stock in the earlier. I think that this is being underappreciated by the market. What are your thoughts? You appear to be a lawyer but are you capable of understanding the science? Very looking forward to hearing your opinion. -GC

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next